Onasemnogene‐abeparvovec administration to premature infants with spinal muscular atrophy

Abstract Twin girls born at 30 weeks' gestation with spinal muscular atrophy (SMA) received onsasemnogene‐abeparvovec (OA) at 3.5 weeks of life. They had no treatment‐related adverse events, normal acquisition of motor milestones, and normal neurological examination at 19 months. Genotyping rev...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephen M. Brown, Aparna S. Ajjarapu, Divya Ramachandra, Laura Blasco‐Pérez, Mar Costa‐Roger, Eduardo F. Tizzano, Charlotte J. Sumner, Katherine D. Mathews
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Annals of Clinical and Translational Neurology
Online Access:https://doi.org/10.1002/acn3.52213
Tags: Add Tag
No Tags, Be the first to tag this record!